Skip to content
drillr.ai

NBIX

Neurocrine Biosciences, Inc.

NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$173.00+1.24%

Price as of Jul 20, 2026

NBIX news

Neurocrine Biosciences, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

    Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, July 9, 2026 Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026. The schedule for the press release

    PR Newswire ·

  2. Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

    Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia PR Newswire SAN DIEGO, July 1, 2026 SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723944-1&h=2112772899&u=http%3A%2F%2Fwww.neurocrine.com%2F&a=Neurocrine+Biosciences%2C+Inc.) (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and to

    PR Newswire ·

  3. Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period

    Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period PR Newswire SAN DIEGO, June 15, 2026 * Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing through 2 years * VYKAT XR d

    PR Newswire ·

  4. Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026

    Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 PR Newswire SAN DIEGO, June 15, 2026 * Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY * Cross-sectional caregiver survey data showed universal satisfaction with CRENESSITY,

    PR Newswire ·

  5. Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026

    Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 PR Newswire SAN DIEGO, June 15, 2026 * Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose * Among participants who were overweight or obese at baseline, 3

    PR Newswire ·

  6. Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients

    Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients PR Newswire SAN DIEGO, June 8, 2026 * New 48-week KINECT(®) 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnormal Involuntary Movement Scale total score); INGREZZA

    PR Newswire ·

  7. Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

    Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026 PR Newswire SAN DIEGO, June 3, 2026 * Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuum * New data demonstrate the effect of CRENESSITY on long-term androgen control and glucocorticoid dose reduc

    PR Newswire ·

  8. Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

    Neurocrine Biosciences to Present at Upcoming Investor Conferences in June PR Newswire SAN DIEGO, May 26, 2026 SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: (https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.html) * William Blair 46(th) Annual Growth Stock Conference. Fireside chat on Tuesday, June 2, 2026 at 10:40 AM CT (11:40 AM ET) in Chicag

    PR Newswire ·

  9. Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

    Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules PR Newswire SAN DIEGO, May 18, 2026 * Clinician survey showed 90% of patients with mild tardive dyskinesia experienced emotional, social or physical impairment * Following initiation of INGREZZA, 96% of patients with mild tardive dyskinesia showed clinician-reported improvement in uncontrolled movements; of those patients, 8

    PR Newswire ·

  10. Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

    Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics PR Newswire SAN DIEGO, May 18, 2026 * Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome * Adds recently launched therapy with strong early adoption and meaningful commercial potential SAN DIEGO, May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690470-1&h=4204494429&u=https%3A

    PR Newswire ·

  11. Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

    Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia PR Newswire SAN DIEGO, May 6, 2026 * New algorithms developed by expert clinical endocrinologists provide clear, practical recommendations for healthcare providers to reduce supraphysiologic glucocorticoid (GC) doses in patients with classic congenital adrenal hyperplasia (CAH) after st

    PR Newswire ·

  12. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

    BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. XOMA Royalty Corporation (Nasdaq – XOMA) Under the terms of the Merger Agreement, XOMA will be acquired by Ligand Pharmaceuticals Incorporated (Nasdaq - LGND) fo

    Globe Newswire ·

  13. Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

    Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist PR Newswire SAN DIEGO, May 4, 2026 * NBIP-'2118 targets a new, non-incretin mechanism for weight loss with lean mass preservation SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679026-1&h=152129197&u=https%3A%2F%2Fwww.neurocrine.com%2F&a=Neurocrine+Biosciences%2C+Inc.) (Nasda

    PR Newswire ·

  14. Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

    Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia PR Newswire SAN DIEGO, May 1, 2026 * At two years, 60% of patients who were overweight or obese at baseline experienced clinically meaningful improvements in body mass index, and 61% of those with insulin resistance at baseline were no longer in

    PR Newswire ·

  15. Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale

    Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale PR Newswire SAN DIEGO, April 29, 2026 * Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA(®) (valbenazine) capsules across the KINECT(®) clinical program * Publication establishes a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS™) SAN DIEGO, Apri

    PR Newswire ·

  16. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)

    BALA CYNWYD, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Avanos Medical, Inc. (NYSE – AVNS) Under the terms of the Merger Agreement, Avanos Medical will be acquired by affiliates of American Industrial Partners (“AIP

    Globe Newswire ·

  17. Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

    Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results PR Newswire SAN DIEGO, April 14, 2026 Conference Call and Webcast Scheduled for Tuesday, May 5 SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2026. (https://mma.prnewswire.com/media/6788

    PR Newswire ·

  18. Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR

    Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR PR Newswire SAN DIEGO, April 14, 2026 * INGREZZA showed higher rates of long-term treatment continuation and lower switching between medications compared to AUSTEDO XR (deutetrabenazine) in a real-world claims analysis among adults with tardive dyskinesia * Higher continuation with INGREZZA was observed early i

    PR Newswire ·

  19. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)

    BALA CYNWYD, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Soleno Therapeutics, Inc. (Nasdaq – SLNO) Under the terms of the Merger Agreement, Soleno will be acquired by Neurocrine Biosciences, Inc. (Nasdaq - NBIX) for $5

    Globe Newswire ·

  20. Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

    Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer PR Newswire SAN DIEGO, March 17, 2026 SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4643400-1&h=242008069&u=https%3A%2F%2Fwww.neurocrine.com%2F&a=Neurocrine+Biosciences%2C+Inc.) (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role

    PR Newswire ·